1h Free Analyst Time
Autism - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H2 2020, provides an overview of the Autism (Central Nervous System) pipeline landscape.
Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 21, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAutism - Overview
Autism - Therapeutics Development
Autism - Therapeutics Assessment
Autism - Companies Involved in Therapeutics Development
Autism - Drug Profiles
Autism - Dormant Projects
Autism - Discontinued Products
Autism - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Autism, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Autism - Pipeline by 4D Pharma Plc, H2 2020
- Autism - Pipeline by AgeneBio Inc, H2 2020
- Autism - Pipeline by AgoneX Biopharmaceuticals Inc, H2 2020
- Autism - Pipeline by AsiaBiome, H2 2020
- Autism - Pipeline by Benuvia Therapeutics Inc, H2 2020
- Autism - Pipeline by Blackthorn Therapeutics Inc, H2 2020
- Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2020
- Autism - Pipeline by Cennerv Pharma (S) Pte Ltd, H2 2020
- Autism - Pipeline by ChunLab Inc, H2 2020
- Autism - Pipeline by Cox Biosciences LLC, H2 2020
- Autism - Pipeline by Curemark LLC, H2 2020
- Autism - Pipeline by Cytocom Inc, H2 2020
- Autism - Pipeline by Epigen Biosciences Inc, H2 2020
- Autism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
- Autism - Pipeline by Finch Therapeutics Group, H2 2020
- Autism - Pipeline by GW Pharmaceuticals Plc, H2 2020
- Autism - Pipeline by Immuron Ltd, H2 2020
- Autism - Pipeline by Intra-Cellular Therapies Inc, H2 2020
- Autism - Pipeline by Johnson & Johnson, H2 2020
- Autism - Pipeline by MD Healthcare Inc, H2 2020
- Autism - Pipeline by Neurochlore, H2 2020
- Autism - Pipeline by Omeros Corp, H2 2020
- Autism - Pipeline by OptiNose US Inc, H2 2020
- Autism - Pipeline by Oryzon Genomics SA, H2 2020
- Autism - Pipeline by Ovensa Inc, H2 2020
- Autism - Pipeline by Panorama Research Inc, H2 2020
- Autism - Pipeline by Park Active Molecules, H2 2020
- Autism - Pipeline by Reviva Pharmaceuticals Inc, H2 2020
- Autism - Pipeline by RogCon Inc, H2 2020
- Autism - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, H2 2020
- Autism - Pipeline by Scioto Biosciences Inc, H2 2020
- Autism - Pipeline by Sengenics International Pte Ltd, H2 2020
- Autism - Pipeline by Sosei Heptares, H2 2020
- Autism - Pipeline by Stem Cell Medicine Ltd, H2 2020
- Autism - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2020
- Autism - Pipeline by Therapix Biosciences Ltd, H2 2020
- Autism - Pipeline by Zelira Therapeutics Ltd, H2 2020
- Autism - Dormant Projects, H2 2020
- Autism - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Autism - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Autism, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- AgeneBio Inc
- AgoneX Biopharmaceuticals Inc
- AsiaBiome
- Benuvia Therapeutics Inc
- Blackthorn Therapeutics Inc
- BrainStorm Cell Therapeutics Inc
- Cennerv Pharma (S) Pte Ltd
- ChunLab Inc
- Cox Biosciences LLC
- Curemark LLC
- Cytocom Inc
- Epigen Biosciences Inc
- F. Hoffmann-La Roche Ltd
- Finch Therapeutics Group
- GW Pharmaceuticals Plc
- Immuron Ltd
- Intra-Cellular Therapies Inc
- Johnson & Johnson
- MD Healthcare Inc
- Neurochlore
- Omeros Corp
- OptiNose US Inc
- Oryzon Genomics SA
- Ovensa Inc
- Panorama Research Inc
- Park Active Molecules
- Reviva Pharmaceuticals Inc
- RogCon Inc
- Rugen Therapeutics R&D (Shanghai) Co Ltd
- Scioto Biosciences Inc
- Sengenics International Pte Ltd
- Sosei Heptares
- Stem Cell Medicine Ltd
- Sumitomo Dainippon Pharma Co Ltd
- Therapix Biosciences Ltd
- Zelira Therapeutics Ltd
